• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ovintiv Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    2/26/25 5:03:22 PM ET
    $OVV
    Oil & Gas Production
    Energy
    Get the next $OVV alert in real time by email
    8-K
    0001792580false00017925802025-02-262025-02-26

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 26, 2025

     

     

    Ovintiv Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39191

    84-4427672

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    Suite 1700, 370 17th Street

     

    Denver, Colorado

     

    80202

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 303 623-2300

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.01 per share

     

    OVV

     

    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On February 26, 2025, Ovintiv Inc. (the “Company”) issued a news release announcing its financial and operating results for its fourth quarter and full year ended December 31, 2024. In connection with this announcement, the Company provided an earnings release and certain selected and supplemental financial information. A copy of the news release and supplemental financial information are attached as Exhibit 99.1 and 99.2 to this Current Report on Form 8-K.

     

    The information contained in this report, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

    Item 8.01 Other Events.

    In its February 26, 2025 news release, the Company also announced that its Board of Directors had declared a quarterly dividend of $0.30 per share on the Company’s outstanding common stock. The dividend is payable on March 31, 2025 to holders of record at the close of business on March 14, 2025. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8‑K.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit No.

    Exhibit Description

    Exhibit 99.1

    News Release dated February 26, 2025.

    Exhibit 99.2

    Selected and Supplemental Financial Information.

    Exhibit 104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Ovintiv Inc.

     

     

     

     

     

    Date:

    February 26, 2025

    By:

    /s/ Dawna I. Gibb

     

     

     

    Name: Dawna I. Gibb
    Title: Assistant Corporate Secretary

     


    Get the next $OVV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OVV

    DatePrice TargetRatingAnalyst
    3/26/2025$57.00Overweight
    Morgan Stanley
    3/24/2025$55.00 → $57.00Market Perform → Outperform
    BMO Capital Markets
    1/13/2025$55.00 → $54.00Neutral → Buy
    BofA Securities
    7/18/2024$65.00Outperform
    Wolfe Research
    6/14/2024$60.00In-line → Outperform
    Evercore ISI
    4/10/2024$69.00Overweight
    Barclays
    12/6/2023$61.00 → $58.00Neutral → Overweight
    JP Morgan
    11/22/2023$48.00 → $52.00Neutral → Buy
    Citigroup
    More analyst ratings